Document:

EX-10.21

 Exhibit 10.21 

Common Share Membership Agreement 

This Common Share Membership Agreement (this “Agreement”) is made as of December 16, 2013 (the “Admission
Date”), by and between Spark Therapeutics, LLC (the “Company”) and Katherine High, MD (the “Member”). 

For valuable consideration, receipt of which is acknowledged, the parties hereto agree as follows: 

1. Defined Terms. 
 (a)
Capitalized terms used but not otherwise defined herein shall have the meaning assigned to such terms in the Amended and Restated Limited Liability Company Agreement of the Company, dated as of October 14, 2013, as amended from time to time
(the “LLC Agreement”). 
 (b) For purposes of this Agreement: 

(1) “Change in Control” means (i) any merger, reorganization, consolidation, recapitalization or other transaction or
series of related transactions, whether or not the Company is the surviving or continuing entity in such transaction, and whether or not the Company is a party thereto, that results in the holders of Shares immediately prior to such transaction or
transactions holding, immediately after such transaction or transactions (whether by virtue of securities issued as consideration for the transaction or otherwise), less than 50% of the voting power of the surviving, continuing or purchasing entity;
or (ii) any sale, lease or other disposition of all or substantially all of the assets (tangible or intangible) of the Company and its subsidiaries, if any, taken as a whole. For avoidance of doubt, the sale of Shares by the Company in
connection with a bona fide equity financing of the Company shall not be deemed a Change in Control. 
 (2) “Member Shares”
means 2,000,000 Series 2 Common Shares. 
 (3) “Vesting Commencement Date” shall be December 16, 2013. 

2. Grant of Member Shares; Admission as Member of the Company. 

(a) As of the Admission Date, the Company hereby issues to the Member, and the Member hereby accepts from the Company, subject to the terms and
conditions set forth in this Agreement and in the LLC Agreement, the Member Shares in consideration for services rendered and to be rendered by the Member to the Company. 

(b) Upon execution of this Agreement the Member shall be admitted as a member of the Company effective as of the Admission Date. The number of
Member Shares acquired by the Member shall be reflected on Schedule A to the LLC Agreement opposite such Member’s name. The Member Shares are hereby designated in accordance with the LLC Agreement as Series 2 Common Shares. 

  
 -1- 

 3. Agreement to be Bound by LLC Agreement. The Member agrees to be bound by the terms and
conditions of the LLC Agreement and authorizes the signature page of this Agreement to be attached to the LLC Agreement, or counterparts thereof. The Member acknowledges receipt of a copy of the LLC Agreement. 

4. Forfeiture of Unvested Shares. 

(a) In the event that the Member ceases to provide services to the Company or any parent or subsidiary of the Company for any reason or no
reason, with or without cause, prior to the completion of vesting of the Member Shares pursuant to this Agreement, all of the Member Shares that are unvested (the “Unvested Shares”) as of the date the Member ceases to provide
services to the Company (such date, as determined in good faith by the Board, the “Cessation of Services Date”) shall be forfeited immediately and automatically to the Company, without payment to the Member. 

(b) The Member Shares shall vest pursuant to the following vesting schedule: (i) as to 25% on the first anniversary of the Vesting
Commencement Date and (ii) the balance of the Member Shares shall vest as to an additional 6.25% at the end of each successive quarterly period following the Vesting Commencement Date until the third anniversary of the Vesting Commencement
Date; provided, however, that the vesting schedule of the Member Shares shall be accelerated in full so that the portion of the Member Shares that constitutes Unvested Shares shall immediately become free from forfeiture upon the closing of a Change
in Control. Notwithstanding anything to the contrary in this Agreement, the Board may in its discretion accelerate the vesting schedule for Unvested Shares, in its entirety or in part, at any time. 

(c) The Member shall not be entitled to any distributions attributable to any Unvested Shares payable to holders of Common Shares as of a
record date after the Cessation of Services Date. 
 5. Section 83(b) Election. The Member understands that it is beneficial for
the Member and the Company for the Member to elect to be taxed at the time the Member Shares are granted to the Member, rather than when and as the Member Shares vest, by filing with the Internal Revenue Service an election under Section 83(b)
of the Internal Revenue Code of 1986 within 30 days from the date the Member Shares are granted to the Member and the Member shall make such timely election. 

THE MEMBER ACKNOWLEDGES THAT IT IS SOLELY THE MEMBER’S RESPONSIBILITY AND NOT THE COMPANY’S TO FILE TIMELY THE ELECTION UNDER
SECTION 83(b), EVEN IF THE MEMBER REQUESTS THE COMPANY OR ITS REPRESENTATIVES TO MAKE THIS FILING ON THE MEMBER’S BEHALF. 
 6.
Purchase Option. 
 (a) In the event that the Member ceases to provide services to the Company or any parent or subsidiary of the
Company for any reason or no reason, with or without cause, after the completion of vesting of all or a portion of the Member Shares pursuant to this Agreement, the Company shall have the right and option (the “Purchase Option”) to
purchase some or all of the Vested Shares (as defined below) from the Member, for a sum equal to the product of (i) the Option Price (as defined below) and (ii) the number of Vested Shares to be purchased (the “Aggregate Option
Price”). 

  
 -2- 

 (b) The Company may exercise the Purchase Option by delivering or mailing to the Member (or his
estate in the event of his death), within 90 days after the Cessation of Services Date, a written notice of exercise of the Purchase Option. Such notice shall specify the number of Vested Shares to be purchased. If and to the extent the Purchase
Option is not so exercised by the giving of such a notice within such 90-day period, the Purchase Option shall automatically expire and terminate effective upon the expiration of such 90-day period. 

(c) Within 10 days after delivery to the Member of the Company’s notice of the exercise of the Purchase Option pursuant to subsection
(b) above, the Company shall pay to the Member the Aggregate Option Price for such Vested Shares. 
 (d) On and after the Option Closing
Date (as defined below), the Company shall not make any distribution to the Member on account of any Vested Shares or permit the Member to exercise any of the privileges or rights of a member of the Company with respect to such Vested Shares, but
shall, in so far as permitted by law, treat the Company as the owner of such Vested Shares. 
 (e) The Option Price may be payable, at the
option of the Company, in cancellation of all or a portion of any outstanding indebtedness of the Member to the Company or in cash (by check) or both. 

(f) The Company may assign its Purchase Option to one or more persons or entities. 

(g) For purposes of this Section 6, the following definitions shall apply: 

(1) “Vested Shares” means Member Shares that are no longer Unvested Shares. 

(2) “Option Closing Date” means the date of the Company’s payment of the Aggregate Option Price to the Member. 

(3) “Option Price” means the fair market value of a Common Share as determined by the Board in good faith, after taking into
consideration a valuation report prepared by an independent appraiser selected by the Board. 
 7. Restrictions on Transfer. 

(a) The Member shall not sell, assign, transfer, pledge, hypothecate or otherwise dispose of, by operation of law or otherwise (collectively
“transfer”), any Unvested Shares, or any interest therein, except that the Member may transfer such Member Shares (i) to or for the benefit of any spouse, children, parents, uncles, aunts, siblings, grandchildren and any other
relatives approved by the Board (collectively, “Approved Relatives”) or to a trust established 

  
 -3- 

 
solely for the benefit of the Member and/or Approved Relatives, provided that such Member Shares shall remain subject to this Agreement (including without limitation the restrictions on
transfer set forth in this Section 7, the Purchase Option and the right of first refusal set forth in Section 8) and the LLC Agreement and such permitted transferee shall, as a condition to such transfer, deliver to the
Company a written instrument confirming that such transferee shall be bound by all of the terms and conditions of this Agreement and the LLC Agreement or (ii) in connection with a Change in Control. 

(b) The Member shall not transfer any Vested Shares, or any interest therein, except in accordance with Section 8 below. 

8. Right of First Refusal. 

(a) If the Member proposes to transfer any Vested Shares, then the Member shall first give written notice of the proposed transfer (the
“Transfer Notice”) to the Company. The Transfer Notice shall name the proposed transferee and state the number of such Member Shares the Member proposes to transfer (the “Offered Shares”), the price per share and
all other material terms and conditions of the transfer. 
 (b) For 30 days following its receipt of such Transfer Notice, the Company shall
have the option to purchase all or part of the Offered Shares at the price and upon the terms set forth in the Transfer Notice. In the event the Company elects to purchase all or part of the Offered Shares, it shall give written notice of such
election to the Member within such 30-day period. Within 10 days after his receipt of such notice, the Company shall deliver or mail to the Member a check in payment of the purchase price for such Offered Shares; provided that if the terms of
payment set forth in the Transfer Notice were other than cash against delivery, the Company may pay for the Offered Shares on the same terms and conditions as were set forth in the Transfer Notice. The date of delivery of such payment shall be
referred to herein as the “Purchase Date”. 
 (c) If the Company does not elect to acquire all of the Offered Shares, the
Member may, within the 30-day period following the expiration of the option granted to the Company under subsection (b) above, transfer the Offered Shares which the Company has not elected to acquire to the proposed transferee, provided that
such transfer shall not be on terms and conditions more favorable to the transferee than those contained in the Transfer Notice. Notwithstanding any of the above, all Offered Shares transferred pursuant to this Section 8 shall remain
subject to this Agreement (including without limitation the restrictions on transfer set forth in Section 7 and the right of first refusal set forth in this Section 8) and the LLC Agreement and such transferee shall, as a
condition to such transfer, deliver to the Company a written instrument confirming that such transferee shall be bound by all of the terms and conditions of this Agreement and the LLC Agreement. 

(d) On and after the Purchase Date, the Company shall not make any distribution to the Member on account of any Offered Shares or permit the
Member to exercise any of the privileges or rights of a member of the Company with respect to such Offered Shares, but shall, in so far as permitted by law, treat the Company as the owner of such Offered Shares. 

  
 -4- 

 (e) The following transactions shall be exempt from the provisions of this Section 8:

 (1) a transfer of Member Shares to or for the benefit of any Approved Relatives, or to a trust established solely for the benefit of the
Member and/or Approved Relatives; 
 (2) any transfer pursuant to an effective registration statement filed by the Company under the
Securities Act of 1933, as amended (the “Securities Act”); and 
 (3) a Change in Control; 

provided, however, that in the case of a transfer pursuant to clause (1) above, such Member Shares shall remain subject to this Agreement
(including without limitation the restrictions on transfer set forth in Section 7 and the right of first refusal set forth in this Section 8) and the LLC Agreement and such transferee shall, as a condition to such transfer,
deliver to the Company a written instrument confirming that such transferee shall be bound by all of the terms and conditions of this Agreement and the LLC Agreement. 

(f) The Company may assign its rights to purchase Offered Shares in any particular transaction under this Section 8 to one or more
persons or entities. 
 (g) The provisions of this Section 8 shall terminate upon the earlier of the following events: 

(1) the closing of the sale of Member Shares in an underwritten public offering pursuant to an effective registration statement filed by the
Company under the Securities Act; or 
 (2) a Change in Control. 

(h) The Company shall not be required (1) to transfer on its books any of the Member Shares which shall have been sold or transferred in
violation of any of the provisions set forth in this Agreement, or (2) to treat as owner of such Member Shares or to make distributions to any transferee to whom any such Member Shares shall have been so sold or transferred. 

9. “Market Stand-off Agreement. The Member hereby agrees that he will not, without the prior written consent of the managing
underwriter, during the period commencing on the date of the final prospectus relating to the initial registration by the Company of the Surviving Corporation Shares or any other equity securities on a registration statement under the Securities Act
(the “IPO”), and ending on the date specified by the Company and the managing underwriter (such period not to exceed 180 days), or such other period as may be requested by the Company or an underwriter to accommodate regulatory
restrictions on (1) the publication or other distribution of research reports and (2) analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any
successor provisions or amendments thereto), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise
transfer or dispose of, directly or indirectly, any Surviving Corporation 

  
 -5- 

 
Shares or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Surviving Corporation Shares (whether such shares or any such securities are then owned by
the Member or are thereafter acquired) or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction described in
clause (i) or (ii) above is to be settled by delivery of Surviving Corporation Shares or other securities, in cash, or otherwise. The foregoing provisions of this Section 9 shall apply only to the IPO, shall not apply to the
sale of any securities to an underwriter pursuant to an underwriting agreement. The underwriters in connection with such registration are intended third-party beneficiaries of this Section 9 and shall have the right, power, and authority
to enforce the provisions hereof as though they were a party hereto. The Member further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this
Section 9 or that are necessary to give further effect thereto. 
 10. Miscellaneous. 

(a) Construction. For purposes of this Agreement, references to Common Shares shall include references to any securities issued in
respect of Common Shares in connection with any reorganization of the Company, reclassification of the Common Shares or other similar transaction, including in connection with the conversion of the LLC into a Corporation pursuant to
Section 12.04 of the LLC Agreement. For the avoidance of doubt, any and all new, substituted or additional securities to which the Member is entitled by reason of his ownership of the Member Shares shall be immediately subject to the forfeiture
provisions, the Purchase Option, the restrictions on transfer and the other provisions of this Agreement in the same manner and to the same extent as the Member Shares. 

(b) Separability of Provisions. Each provision of this Agreement shall be considered separable. To the extent that any provision of this
Agreement is prohibited or ineffective under the Act, this Agreement shall be considered amended to the smallest degree possible in order to make this Agreement effective under the Act (and, if the Act is subsequently amended or interpreted in such
manner as to make effective any provision of this Agreement that was formerly rendered invalid, such provision shall automatically be considered to be valid from the effective date of such amendment or interpretation). 

(c) Waiver; Amendment. Any provision for the benefit of the Company contained in this Agreement may be waived, either generally or in
any particular instance, by the Board. The terms of this Agreement may be amended only by a written instrument duly executed by the Company and the Member. 

(d) Binding Effect. This Agreement shall be binding upon and inure to the benefit of the Company and the Member and their respective
heirs, legal representatives, successors and assigns, subject to the terms of this Agreement and the LLC Agreement. 
 (e) Notice. All
notices required or permitted hereunder shall be delivered in accordance with the provisions of the LLC Agreement. 

  
 -6- 

 (f) Applicable Law. This Agreement shall be construed and enforced in accordance with the
laws of the State of Delaware, including the Act, as interpreted by the courts of the State of Delaware, notwithstanding any rules regarding conflicts or choice of law to the contrary. 

(g) Entire Agreement. This Agreement and the LLC Agreement constitute the full and entire understanding and agreement between the
parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled. 

[Remainder of Page Intentionally Left Blank] 

  
 -7- 

 Executed, in counterpart, as of the Admission Date. 

 

	
	MEMBER:
	
	 /s/ Kathy High

	Name: Kathy High, MD

  

			
	ACCEPTED AND AGREED:
	
	SPARK THERAPEUTICS, LLC
		
	By:	 	 /s/ Jeffrey D. Marrazzo

	Name:	 	Jeffrey D. Marrazzo
	Title	 	Chief Executive Officer

  
 -8-Exhibit 10.1

 

Execution Version

AMENDMENT NO. 1 TO CREDIT AGREEMENT

 

AMENDMENT NO. 1 TO CREDIT
AGREEMENT, dated as of December 23, 2014 (this “Agreement”), by and among Albany Molecular Research, Inc., a
Delaware corporation (the “Borrower”), Barclays Bank PLC, as administrative agent and collateral agent (in such
capacities, the “Administrative Agent”), each Lender party hereto (collectively, the “Lenders”)
and each other Loan Party party hereto.

 

RECITALS:

 

WHEREAS, reference
is hereby made to the Credit Agreement, dated as of October 24, 2014 (as amended, restated, supplemented or otherwise modified
from time to time, the “Credit Agreement”), by and among the Borrower, the lending institutions from time to
time party thereto and Barclays Bank PLC, as Administrative Agent, Collateral Agent, Swing Line Lender and L/C Issuer (capitalized
terms used but not defined herein having the meanings provided in the Credit Agreement);

 

WHEREAS, the Borrower
has delivered to the Administrative Agent a request to increase the Revolving Commitment by an aggregate principal amount of $25,000,000
to be provided by JPMorgan Chase Bank, N.A. on terms identical to those applicable to the existing Revolving Loans (the “Revolving
Commitment Increase”); and

 

WHEREAS, in connection
with such Revolving Commitment Increase and in accordance with Section 10.01 of the Credit Agreement, the Borrower wishes
to make certain amendments and the other modifications to the Credit Agreement set forth herein.

 

NOW, THEREFORE,
in consideration of the premises and agreements, provisions and covenants herein contained, the parties hereto agree as follows:

 

		1.	Credit Agreement Amendments. Effective as of the Effective Date (as defined below), the
Credit Agreement is hereby amended as follows:

 

		(a)	Section 1.01 of the Credit Agreement is hereby amended by inserting the following new definitions
in their correct alphabetical order:

 

“Amendment
No. 1” shall mean Amendment No. 1 to this Agreement, dated as of December 23, 2014, among the Borrower, the other Loan
Parties party thereto, the Lenders party thereto and the Administrative Agent.

 

“Amendment
No. 1 Effective Date” shall mean the “Effective Date” under and as defined in Amendment No. 1.

 

		(b)	The definition of “L/C Issuer” is hereby amended and restated in its entirety by replacing
the existing definition with the following:

 

“L/C Issuer”
means (i) Barclays Bank PLC, in its capacity as issuer of Letters of Credit under Section 2.05(a), and its successor or
successors in such capacity, (ii) Morgan Stanley Bank N.A., in its capacity as issuer of Letters of Credit under Section 2.05(a),
and its successor or successors in such capacity, (iii) JPMorgan Chase Bank, N.A., in its capacity as issuer of Letters of Credit
under Section 2.05(a), and its successor or successors in such capacity and (iv) any other Revolving Lender (or, if reasonably
satisfactory to the Administrative Agent, an Affiliate of any Revolving Lender) which the Borrower shall have designated as an
“L/C Issuer” by notice to the Administrative Agent with the consent of such other Revolving Lender or Affiliate of
a Revolving Lender, as applicable.

 

    	 

    	 

    

 

		(c)	The definition of “L/C Issuer Sublimit” is hereby amended and restated in its entirety
by replacing the existing definition with the following:

 

“L/C Issuer Sublimit”
means (a) with respect to Barclays Bank PLC, $5,000,000 of the L/C Sublimit, (b) with respect to Morgan Stanley Bank N.A., $5,000,000
of the L/C Sublimit and (c) with respect to JPMorgan Chase Bank, N.A., $5,000,000 of the L/C Sublimit. The L/C Issuer Sublimit
is a part of, and not in addition to, the Revolving Committed Amount or the L/C Sublimit.

 

		(d)	The definition of “Lead Arrangers” is hereby amended and restated in its entirety by
replacing the existing definition with the following:

 

“Lead Arrangers”
means Barclays Bank PLC, Morgan Stanley Senior Funding, Inc. and J.P. Morgan Securities LLC, in their capacities as joint lead
arrangers, or any successor lead arrangers.

 

		(e)	The definition of “Required Lenders” is hereby amended and restated in its entirety
by replacing the existing definition with the following:

 

“Required Lenders”
means, at any time of determination, Lenders whose aggregate Credit Exposure constitutes more than 50% of the Credit Exposure of
all Lenders at such time; provided, however, that Required Lenders shall in any case include each Lender whose Credit
Exposure constitutes 25% or more of the aggregate Credit Exposure of all Lenders; provided, further, that if any
Lender shall be a Defaulting Lender at such time then there shall be excluded from the determination of Required Lenders such Lender
and its Credit Exposure at such time.

 

		(f)	Schedule 2.01 of the Credit Agreement is hereby amended and restated in its entirety by
replacing the existing Schedule 2.01 with the new Schedule 2.01 attached to this Agreement as Exhibit A.

 

		(g)	Schedule 5.12 of the Credit Agreement is hereby amended and restated in its entirety by
replacing the existing Schedule 5.12 with the new Schedule 5.12 attached to this Agreement as Exhibit B.

 

		(h)	Section 6.09(b)(ii) of the Credit Agreement is hereby amended by replacing the words “forty-five
(45) days” with “ninety (90) days”.

 

		(i)	Section 10.02(a)(ii) of the Credit Agreement is hereby amended by inserting the following
at the end:

 

JPMorgan Chase Bank, N.A.

10 S. Dearborn

Chicago, IL 60603

Attn: Dinesh Chandrasekaran

Phone: (91-80) 66766130 ext. 66130
or (91-80) 66762620 ext. 62620

 

    	2

    	 

    

 

Fax: (214) 307-6874

Email: Chicago.lc.agency.servicing.team@jpmchase.com

 

		(j)	All references to “Increase Effective Date,” “Increase Joinder,” “Incremental
Revolving Commitment Percentage,” “Incremental Revolving Commitments,” “Incremental Revolving Increase,”
“Incremental Revolving Loans” and “Section 2.15” contained in the Credit Agreement shall be removed in
its entirety and the contents of Section 2.15 of the Credit Agreement shall be replaced with “[Reserved]”.

 

		2.	Effective Date Conditions. This Agreement will become effective on the date (the “Effective
Date”) on which each of the following conditions have been satisfied (or waived) in accordance with the terms therein:

 

		(i)	this Agreement shall have been executed and delivered by the Borrower, the other Loan Parties,
the Administrative Agent and the Lenders;

 

		(ii)	the Administrative Agent shall have received a certificate of the Borrower dated as of the Effective
Date signed by a Responsible Officer of the Borrower (i) (A) certifying and attaching the resolutions or similar consents adopted
by the Borrower approving or consenting to this Agreement and the Revolving Commitment Increase, (B) certifying that the certificate
or articles of incorporation and by-laws of the Borrower either (x) have not been amended since the Closing Date or (y) are
attached as an exhibit to such certificate, (C) certifying that the certificate of good standing of the Borrower as of a recent
date is attached as an exhibit to such certificate and (D) certifying as to the incumbency and specimen signature of each officer
executing this Agreement and any related documents on behalf of the Borrower and (ii) certifying as to the matters set forth in
clauses (v) and (vi) below;

 

		(iii)	(A) all fees and out-of-pocket expenses for which invoices have been presented at least three Business
Days prior to the Effective Date (including the reasonable fees and expenses of legal counsel) required to be paid or reimbursed
by the Borrower pursuant to Section 10.04 of the Credit Agreement in connection with this Agreement shall have been paid
or reimbursed and (B) all accrued and unpaid interest, fees or other amounts then due and payable in respect of the Loans outstanding
immediately prior to effectiveness of this Agreement, to the extent not otherwise waived, shall have been paid;

 

		(iv)	the Administrative Agent shall have received an opinion of Willkie Farr & Gallagher LLP, in
form and substance reasonably satisfactory to the Administrative Agent;

 

		(v)	all representations and warranties made by each Loan Party contained in the Credit Agreement and
in the other Loan Documents shall be (i) in the case of representations and warranties qualified by “materiality,”
“Material Adverse Effect” or similar language, true and correct in all respects and (ii) in the case of all other representations
and warranties, true and correct in all material respects, in each case, both immediately before and after giving effect to the
Effective Date, except to the extent that such representations and warranties specifically refer to an earlier date, in which case
they shall be true and correct on the basis set forth above as of such earlier date; and

 

    	3

    	 

    

 

		(vi)	no Default or Event of Default exists or would result, both immediately before and after giving
effect to the Effective Date.

 

		3.	Representations and Warranties. By its execution of this Agreement, each Loan Party hereby
represents and warrants that:

 

		(i)	the execution, delivery and performance by each Loan Party of this Agreement (a) have been duly
authorized by all necessary corporate, partnership, limited liability company or other organizational action and (b) do not and
will not (x) contravene the terms of any of such Person’s Organization Documents, (y) conflict with or result in any breach
or contravention of, or the creation of any Lien (other than Permitted Liens) under, any Contractual Obligation to which such Person
is a party or any order, injunction, writ or decree of any Governmental Authority or any arbitral award to which such Person or
its property is subject except in the case of this clause (y) any such conflict, breach or contravention that would not
reasonably be expected individually or in the aggregate to have a Material Adverse Effect or (z) violate any Law, except in any
case for such violations that would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect;
and

 

		(ii)	this Agreement has been duly executed and delivered by each Loan Party that is party thereto and
this Agreement constitutes a legal, valid and binding obligation of such Loan Party, enforceable against each Loan Party that is
party thereto in accordance with its terms, except (i) as such enforceability may be limited by applicable bankruptcy, insolvency,
examinership, reorganization, moratorium or similar laws affecting the enforcement of creditors’ rights generally and (ii)
that rights of acceleration and the availability of equitable remedies may be limited by equitable principles of general applicability
(regardless of whether enforcement is sought by proceedings in equity or at law).

 

		4.	Reaffirmation of the Loan Parties. Each Loan Party hereby consents to the amendment of the
Credit Agreement effected hereby and confirms and agrees that, notwithstanding the effectiveness of this Agreement, each Loan Document
to which such Loan Party is a party is, and the obligations of such Loan Party contained in the Credit Agreement, this Agreement
or in any other Loan Document to which it is a party are, and shall continue to be, in full force and effect and are hereby ratified
and confirmed in all respects, in each case as amended by this Agreement. For greater certainty and without limiting the foregoing,
each Loan Party hereby confirms that the existing security interests granted by such Loan Party in favor of the Administrative
Agent for the benefit of the Finance Parties pursuant to the Loan Documents in the Collateral described therein shall continue
to secure the obligations of the Loan Parties under the Credit Agreement and the other Loan Documents as and to the extent provided
in the Loan Documents.

 

		5.	Amendment, Modification and Waiver. This Agreement may not be amended, modified or waived
except as permitted by Section 10.01 of the Credit Agreement.

 

		6.	Counterparts; Integration. This Agreement may be executed in counterparts (and by different
parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall
constitute a single contract. This Agreement, the Credit Agreement and the other Loan Documents, and any separate letter agreements
with respect to fees payable to the Administrative Agent, constitute the entire contract among the parties relating to the subject
matter hereof and supersede any and all previous agreements and understandings, oral or written, relating to the subject matter
hereof; provided that, notwithstanding anything contained herein, the Fee Letter shall survive the Closing Date. Delivery
of an executed counterpart of a signature page of this Agreement by telecopier shall be effective as delivery of a manually executed
counterpart of this Agreement.

 

    	4

    	 

    

 

		7.	Severability. Any provision of this Agreement held to be invalid, illegal or unenforceable
in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such invalidity, illegality or unenforceability
without affecting the validity, legality and enforceability of the remaining provisions hereof; and the invalidity of a particular
provision in a particular jurisdiction shall not invalidate such provision in any other jurisdiction.

 

		8.	Governing Law. This Agreement and any claims, controversy, dispute or cause of action (whether
in contract or tort or otherwise) based upon, arising out of or relating to this Agreement, the Credit Agreement and the other
Loan Documents, and the transactions contemplated hereby and thereby shall be governed by, and construed in accordance with, the
Law of the State of New York.

 

		9.	WAIVER OF JURY TRIAL. Each party hereby waives,
to the fullest extent permitted by applicable Laws, any right it may have to a trial by jury in any legal proceeding directly or
indirectly arising out of or relating to this Agreement, any other Loan Document or the transactions contemplated hereby (whether
based on contract, tort or any other theory). Each party hereto (a) certifies that no representative, agent or attorney of any
other party has represented, expressly or otherwise, that such other party would not, in the event of litigation, seek to enforce
the foregoing waiver and (b) acknowledges that it and the other parties hereto have been induced to enter into this Agreement by,
among other things, the mutual waivers and certifications in this Section 9.

 

		10.	Loan Document. On and after the Effective Date, this Agreement shall constitute a “Loan
Document” for all purposes of the Credit Agreement and the other Loan Documents (it being understood that for the avoidance
of doubt this Agreement may be amended or waived solely by the parties hereto as set forth in Section 5 hereof).

 

[Signature
pages to follow]

 

    	5

    	 

    

 

IN WITNESS WHEREOF,
each of the undersigned has caused its duly authorized officer to execute and deliver this Agreement as of the date first set forth
above.

 

	 	ALBANY MOLECULAR RESEARCH, INC., as the Borrower
	 	 
	 	By:  	/s/ Michael M. Nolan
	 	 	Name: Michael M. Nolan
	 	 	Title: Treasurer
	 	 	 
	 	ALO ACQUISITION LLC, as a Guarantor
	 	 
	 	By:  	/s/ Michael M. Nolan
	 	 	Name: Michael M. Nolan
	 	 	Title: Managing Member
	 	 	 
	 	AMRI BURLINGTON, INC., as a Guarantor
	 	 
	 	By:  	/s/ Michael M. Nolan
	 	 	Name: Michael M. Nolan
	 	 	Title: Treasurer
	 	 	 
	 	AMRI RENSSELAER, INC., as a Guarantor
	 	 
	 	By:  	/s/ Michael M. Nolan
	 	 	Name: Michael M. Nolan
	 	 	Title: Treasurer

 

[Signature Page to Amendment No. 1 to
Credit Agreement]

 

    	 

    	 

    

 

	 	CEDARBURG PHARMACEUTICALS, INC., as a Guarantor
	 	 
	 	By:  	/s/ Michael M. Nolan
	 	 	Name: Michael M. Nolan
	 	 	Title: Treasurer
	 	 	 
	 	OSO BIOPHARMACEUTICALS MANUFACTURING LLC, as a Guarantor
	 	 
	 	By:  	/s/ Michael M. Nolan
	 	 	Name: Michael M. Nolan
	 	 	Title: Treasurer

 

[Signature Page to Amendment No. 1 to
Credit Agreement]

 

    	 

    	 

    

 

	 	BARCLAYS BANK PLC, 
	 	as the Administrative Agent and as a Lender
	 	 	 
	 	By:  	/s/ John Skrobe
	 	 	Name: John Skrobe
	 	 	Title: Managing Director

 

[Signature Page to Amendment No. 1 to
Credit Agreement]

 

    	 

    	 

    

 

	 	MORGAN STANLEY BANK N.A., 
	 	as a Lender
	 	 	 
	 	By:  	/s/ Alice Lee
	 	 	Name: Alice Lee
	 	 	Title: Authorized Signatory

 

[Signature Page to Amendment No. 1 to
Credit Agreement]

 

    	 

    	 

    

 

	 	JPMorgan Chase Bank, N.A.,
	 	as a Lender and as L/C Issuer
	 	 	 
	 	By:  	/s/ Thomas Strasenburgh
	 	 	Name: Thomas Strasenburgh
	 	 	Title: V.P. & Authorized Officer

 

[Signature Page to Amendment No. 1 to
Credit Agreement]

 

    	 

    	 

    

 

EXHIBIT A

 

Schedule 2.01

Lenders
and Commitments

 

	Revolving Lender	 	Revolving Commitment	 	 	Revolving Commitment
 Percentage	 
	Barclays Bank PLC	 	$	25,000,000	 	 	 	33.34	%
	Morgan Stanley Bank N.A.	 	$	25,000,000	 	 	 	33.33	%
	JPMorgan Chase Bank, N.A.	 	$	25,000,000	 	 	 	33.33	%
	Total	 	$	75,000,000	 	 	 	100	%

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00239-of-00352.parquet"}]]